Skip to main content

Table 2 Five-year outcomes of 5 different endpoints for all female patients with primary, non-metastatic, unilateral breast cancer treated at the Heidelberg Breast Care Unit between 01 January 2003 and 31 December 2012

From: Prognosis of breast cancer molecular subtypes in routine clinical care: A large prospective cohort study

 

All patients (including in-situ) n = 4102 (including 499 in-situ cases)

Patients with invasive cancer (excluding in-situ) n = 3603

LCR [%] (95 % CI)

96.1 (95.3; 96.9)

96.1 (95.3; 96.9)

DFS [%] (95 % CI)

84.9 (83.6; 86.2)

83.7 (82.2; 85.2)

DDFS [%] (95 % CI)

86.9 (85.7; 88.1)

85.7 (84.3; 87.1)

OS [%] (95 % CI)

91.3 (90.2; 92.4)

90.5 (89.3; 91.7)

ROS [%] (95 % CI)

95.5 (94.3; 96.7)

94.7 (93.4; 96.0)

  1. CI confidence interval, LCR local recurrence rate, DFS disease-free survival, DDFS distant disease-free survival, OS observed overall survival, ROS relative overall survival